http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106635972-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-392 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-25 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0656 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-077 |
| filingDate | 2017-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106635972-B |
| titleOfInvention | Fibroblastic culture medium and preparation method thereof |
| abstract | The present invention relates to a kind of inductions of inductive pluripotent stem cells into fibroblastic culture medium and preparation method thereof.The culture medium includes basic culture solution and additive, and the basic culture solution is the H-DMEM culture solution and F12 culture solution that volume ratio is 1:0.5~2ï¼›With the densimeter in the basic culture solution, the additive includes following component: nonessential amino acid, Glutamine Derivatives, insulin, hydrocortisone, transferrins, sodium selenite, fibroblast growth factor, estradiol, progesterone, 8- bromine adenosine cyclophosphate, human follicle stimulating hormone.The culture medium can be obtained compared with the higher fibroblast differentiation probability of the prior art, and passage can be stablized, improve the growth rate of cell, fibroblastic seed cell source is provided for skin tissue engineering, whole process does not use serum simultaneously, animal derived pathogen bring risk is effectively avoided, the safety of clinical application is improved. |
| priorityDate | 2017-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 115.